Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Phase 1 Completed
32 enrolled
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1 Completed
14 enrolled
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Phase 1 Completed
38 enrolled 14 charts
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Phase 2 Completed
78 enrolled 15 charts
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Completed
9 enrolled
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
94 enrolled
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 2 Completed
21 enrolled 11 charts
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Phase 2 Completed
17 enrolled 12 charts
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
Phase 1 Completed
59 enrolled
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Phase 1/2 Completed
61 enrolled 10 charts
RENAL
Phase 1 Completed
31 enrolled 30 charts
RACE
Phase 1 Completed
31 enrolled
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
Phase 1 Completed
52 enrolled
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Phase 1/2 Completed
17 enrolled 3 charts
Study of the Glutaminase Inhibitor CB-839 in Leukemia
Phase 1 Completed
43 enrolled
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
Phase 1 Completed
12 enrolled
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Phase 1 Completed
56 enrolled
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Phase 1 Completed
72 enrolled
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1 Completed
8 enrolled
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed